Author
Marc G. Ghany
Other affiliations: University Medical Center New Orleans, University of Michigan, Chiron Corporation ...read more
Bio: Marc G. Ghany is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Hepatitis C & Hepatitis B. The author has an hindex of 63, co-authored 198 publications receiving 18849 citations. Previous affiliations of Marc G. Ghany include University Medical Center New Orleans & University of Michigan.
Papers published on a yearly basis
Papers
More filters
TL;DR: This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
3,013 citations
TL;DR: The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV) as mentioned in this paper.
1,117 citations
TL;DR: It is indicated that treatment with an insulin‐sensitizing agent can lead to improvement in biochemical and histological features of NASH and support the role of insulin resistance in the pathogenesis of this disease.
713 citations
University of Michigan1, National Institutes of Health2, University of California, Irvine3, Saint Louis University4, Virginia Commonwealth University5, University of Colorado Denver6, University of Southern California7, University of Texas Southwestern Medical Center8, University of Connecticut9, Harvard University10, University of Washington11, United States Department of Veterans Affairs12
TL;DR: It was found that maintenance peginterferon did not reduce the incidence of HCC in the HALT-C cohort, and baseline clinical and laboratory features predicted risk for HCC.
559 citations
Virginia Commonwealth University1, Saint Louis University2, University of Southern California3, University of Washington4, University of Colorado Denver5, University of Michigan6, University of California, Irvine7, University of Connecticut8, University of Texas Southwestern Medical Center9, Harvard University10, National Institutes of Health11, United States Department of Veterans Affairs12
TL;DR: The most effective therapy currently available for treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin, which was evaluated in patients who were nonresponders to previous interferon-based therapy as discussed by the authors.
486 citations
Cited by
More filters
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
8,253 citations
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
7,851 citations
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
6,964 citations
01 Jan 2010
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Abstract: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated. The full version of the new guidelines is available on the AASLD Web site at http://www.aasld.org/practiceguidelines/ Documents/Bookmarked%20Practice%20Guidelines/ HCCUpdate2010.pdf. Here, we briefly describe only new or changed recommendations.
6,642 citations
TL;DR: In patients with chronic hepatitis C, initial therapy withinterferon and ribavirin was more effective than treatment with interferon alone.
Abstract: Background Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatment of patients with chronic hepatitis C. Methods We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransferases and by liver biopsy. Results The rate of sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was higher among patients who received combination therapy for either 24 weeks (70 of 228 patients, 31 percent) or 48 weeks (87 of 228 patients, 38 percent) than among patients who received interfe...
3,531 citations